Blood "signatures" enhance cancer therapy
A multi-center team, led by Vanderbilt-Ingram Cancer Center investigators, has discovered a "signature" of proteins in the blood that predicts which non-small-cell lung cancer patients will live longer when they are treated with certain targeted cancer therapies. Such targeted cancer therapies are the newest generation of anti-cancer drugs. Click here to read more »
Publications from Vanderbilt Medical Center:
The Reporter House Organ VU Medicine
Happening at Vanderbilt...
- New treatment eases pounding pain of migraine.
Read more »
- Clinical trial at Vanderbilt leads to new lung cancer drug. Read more »
- Discovery of reovirus genome offers new hope for vaccines.
Read more »
- New minimially invasive robotic surgery enhances women's urological care. Read more »
- Vanderbilt offers new treatment for macular degeneration.
Read more »
- Study adds new clues to autism. Read more »
- Music therapy at Children's Hospital aids in healing. Read more »
